c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells

STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells

(2010) I. Hazan-Halevy et al.   BLOOD

Protein kinase Cɛ mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2 and ERK1/2)

(2010) M H Aziz et al.   ONCOGENE

Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status

(2009) Alexander Hoellein et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia

(2009) Saman Hewamana et al.   JOURNAL OF CLINICAL ONCOLOGY

c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches

(2008) D. Y. H. Hallaert et al.   BLOOD

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

(2008) F. T. Awan et al.   BLOOD

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers

(2008) C. Pepper et al.   BLOOD

AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance

(2008) K. Balakrishnan et al.   BLOOD

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro

(2008) Lilian Amrein et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Novel Nuclear Factor- B Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine

(2008) S. Hewamana et al.   CLINICAL CANCER RESEARCH

Chronic lymphocytic leukaemia

(2008) G Dighiero et al.   LANCET